Ra Pharmaceuticals Plans $75 Million IPO for October 26th (RARX)
In the last year, Ra Pharmaceuticals generated $6.8 million in revenue and had a net loss of $16.7 million. The company has a market cap of $263.1 million.
Credit Suisse, Jefferies and BMO Capital Markets served as the underwriters for the IPO and SunTrust Robinson Humphrey was co-manager.
Ra Pharmaceuticals provided the following description of their company for its IPO: “We are a clinical-stage biopharmaceutical company using our proprietary peptide chemistry platform to develop novel therapeutics for the treatment of serious diseases that are caused by excessive or uncontrolled activation of the complement system, a critical component of the immune system. Inappropriate activation of the complement system can quickly turn it from a beneficial defense system to an aggressor that plays a major role in immune and inflammatory diseases. We are developing our lead product candidate, RA101495, a convenient self-administered subcutaneous, or SC, injection, which is an injection into the tissue under the skin, for the treatment of paroxysmal nocturnal hemoglobinuria, or PNH. PNH is a rare, chronic, life-threatening, blood disorder where red blood cells are mistakenly attacked and destroyed by the complement system. “.
Ra Pharmaceuticals was founded in 2008 and has 40 employees. The company is located at 87 Cambridge Park Drive, Cambridge, MA 02140, US and can be reached via phone at (617) 401-4060 or on the web at https://www.rapharma.com.
Receive News & Ratings for Ra Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ra Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.